These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

345 related items for PubMed ID: 27127322

  • 21. Favorable outcome of individual regimens containing bedaquiline and delamanid in drug-resistant tuberculosis: A systematic review.
    Putra ON, Yulistiani Y, Soedarsono S, Subay S.
    Int J Mycobacteriol; 2023; 12(1):1-9. PubMed ID: 36926755
    [Abstract] [Full Text] [Related]

  • 22. Bedaquiline for the treatment of drug-resistant tuberculosis.
    Bélard S, Heuvelings CC, Janssen S, Grobusch MP.
    Expert Rev Anti Infect Ther; 2015 May; 13(5):535-53. PubMed ID: 25797824
    [Abstract] [Full Text] [Related]

  • 23. Evaluation of six months sputum culture conversion as a surrogate endpoint in a multidrug resistant-tuberculosis trial.
    Meyvisch P, Kambili C, Andries K, Lounis N, Theeuwes M, Dannemann B, Vandebosch A, Van der Elst W, Molenberghs G, Alonso A.
    PLoS One; 2018 May; 13(7):e0200539. PubMed ID: 30024924
    [Abstract] [Full Text] [Related]

  • 24. Off-Label Use of Bedaquiline in Children and Adolescents with Multidrug-Resistant Tuberculosis.
    Achar J, Hewison C, Cavalheiro AP, Skrahina A, Cajazeiro J, Nargiza P, Herboczek K, Rajabov AS, Hughes J, Ferlazzo G, Seddon JA, du Cros P.
    Emerg Infect Dis; 2017 Oct; 23(10):1711-3. PubMed ID: 28758889
    [Abstract] [Full Text] [Related]

  • 25. Effectiveness and safety of bedaquiline under conditional access program for treatment of drug-resistant tuberculosis in India: An interim analysis.
    Salhotra VS, Sachdeva KS, Kshirsagar N, Parmar M, Ramachandran R, Padmapriyadarsini C, Patel Y, Mehandru L, Jaju J, Ponnuraja C, Gupta M, Kalaiselvan V, Shamim A, Khaparde S, Swaminathan S, Bedaquiline CAP Site Teams.
    Indian J Tuberc; 2020 Jan; 67(1):29-37. PubMed ID: 32192613
    [Abstract] [Full Text] [Related]

  • 26. Impact of bedaquiline on treatment outcomes of multidrug-resistant tuberculosis in a high-burden country.
    Chesov D, Heyckendorf J, Alexandru S, Donica A, Chesov E, Reimann M, Crudu V, Botnaru V, Lange C.
    Eur Respir J; 2021 Jun; 57(6):. PubMed ID: 33334942
    [Abstract] [Full Text] [Related]

  • 27. Long-term impact of the adoption of bedaquiline-containing regimens on the burden of drug-resistant tuberculosis in China.
    Agnarson AM, Wang XC, Potluri R, Bhandari H, Dhir A, Kambili C, Metz L.
    BMC Infect Dis; 2020 Feb 10; 20(1):113. PubMed ID: 32041542
    [Abstract] [Full Text] [Related]

  • 28. Improved Treatment Outcomes With Bedaquiline When Substituted for Second-line Injectable Agents in Multidrug-resistant Tuberculosis: A Retrospective Cohort Study.
    Zhao Y, Fox T, Manning K, Stewart A, Tiffin N, Khomo N, Leslie J, Boulle A, Mudaly V, Kock Y, Meintjes G, Wasserman S.
    Clin Infect Dis; 2019 Apr 24; 68(9):1522-1529. PubMed ID: 30165431
    [Abstract] [Full Text] [Related]

  • 29. The cost-effectiveness of a bedaquiline-containing short-course regimen for the treatment of multidrug-resistant tuberculosis in South Africa.
    Mpobela Agnarson A, Williams A, Kambili C, Mattson G, Metz L.
    Expert Rev Anti Infect Ther; 2020 May 24; 18(5):475-483. PubMed ID: 32186925
    [Abstract] [Full Text] [Related]

  • 30. Management of drug resistantTB in patients with HIV co-infection.
    Pontali E, Sotgiu G, Centis R, D'Ambrosio L, Spanevello A, Migliori GB.
    Expert Opin Pharmacother; 2015 May 24; 16(18):2737-50. PubMed ID: 26478945
    [Abstract] [Full Text] [Related]

  • 31. Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort.
    Guglielmetti L, Le Dû D, Jachym M, Henry B, Martin D, Caumes E, Veziris N, Métivier N, Robert J, MDR-TB Management Group of the French National Reference Center for Mycobacteria and the Physicians of the French MDR-TB Cohort.
    Clin Infect Dis; 2015 Jan 15; 60(2):188-94. PubMed ID: 25320286
    [Abstract] [Full Text] [Related]

  • 32. Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study.
    Ferlazzo G, Mohr E, Laxmeshwar C, Hewison C, Hughes J, Jonckheere S, Khachatryan N, De Avezedo V, Egazaryan L, Shroufi A, Kalon S, Cox H, Furin J, Isaakidis P.
    Lancet Infect Dis; 2018 May 15; 18(5):536-544. PubMed ID: 29452942
    [Abstract] [Full Text] [Related]

  • 33. Bedaquiline-containing regimens and multidrug-resistant tuberculosis: a systematic review and meta-analysis.
    Hatami H, Sotgiu G, Bostanghadiri N, Abadi SSD, Mesgarpour B, Goudarzi H, Migliori GB, Nasiri MJ.
    J Bras Pneumol; 2022 May 15; 48(2):e20210384. PubMed ID: 35649043
    [Abstract] [Full Text] [Related]

  • 34. Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis.
    Guglielmetti L, Jaspard M, Le Dû D, Lachâtre M, Marigot-Outtandy D, Bernard C, Veziris N, Robert J, Yazdanpanah Y, Caumes E, Fréchet-Jachym M, French MDR-TB Management Group.
    Eur Respir J; 2017 Mar 15; 49(3):. PubMed ID: 28182570
    [Abstract] [Full Text] [Related]

  • 35. Bedaquiline: Introducing a new drug to the MDR TB armamentarium.
    Kambili C.
    Indian J Tuberc; 2016 Jul 15; 63(3):137-138. PubMed ID: 27865232
    [No Abstract] [Full Text] [Related]

  • 36. Outcomes of patients with drug-resistant-tuberculosis treated with bedaquiline-containing regimens and undergoing adjunctive surgery.
    Borisov SE, D'Ambrosio L, Centis R, Tiberi S, Dheda K, Alffenaar JW, Amale R, Belilowski E, Bruchfeld J, Canneto B, Denholm J, Duarte R, Esmail A, Filippov A, Davies Forsman L, Gaga M, Ganatra S, Igorevna GA, Lazaro Mastrapa B, Manfrin V, Manga S, Maryandyshev A, Massard G, González Montaner P, Mullerpattan J, Palmero DJ, Pontarelli A, Papavasileiou A, Pontali E, Romero Leyet R, Spanevello A, Udwadia ZF, Viggiani P, Visca D, Sotgiu G, Migliori GB.
    J Infect; 2019 Jan 15; 78(1):35-39. PubMed ID: 30096332
    [Abstract] [Full Text] [Related]

  • 37. Efficacy of bedaquiline in the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis.
    Wang MG, Wu SQ, He JQ.
    BMC Infect Dis; 2021 Sep 17; 21(1):970. PubMed ID: 34535090
    [Abstract] [Full Text] [Related]

  • 38. A case of primary multidrug-resistant pulmonary tuberculosis with high minimum inhibitory concentration value for bedaquiline.
    Kobayashi M, Motoki Y, Yamagishi T, Hirano H, Nonaka M, Aono A, Mitarai S, Saito T.
    J Infect Chemother; 2022 Aug 17; 28(8):1193-1197. PubMed ID: 35550867
    [Abstract] [Full Text] [Related]

  • 39. Bedaquiline: a novel antitubercular drug for multidrug-resistant tuberculosis.
    Nagabushan H, Roopadevi HS.
    J Postgrad Med; 2014 Aug 17; 60(3):300-2. PubMed ID: 25121373
    [Abstract] [Full Text] [Related]

  • 40. Unexpected high prevalence of resistance-associated Rv0678 variants in MDR-TB patients without documented prior use of clofazimine or bedaquiline.
    Villellas C, Coeck N, Meehan CJ, Lounis N, de Jong B, Rigouts L, Andries K.
    J Antimicrob Chemother; 2017 Mar 01; 72(3):684-690. PubMed ID: 28031270
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.